

ASX Announcement

25 October 2021

Regeneus (ASX: RGS) Investor Update Webcast Notification

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today advises it will be conducting a live webcast and Q&A with Regeneus CEO Karolis Rosickas on **Thursday 4th November** at **2:00pm** Australian Eastern Daylight Time (AEDT).

Investors are invited to join the session where Mr. Rosickas will provide an update on on the Company's progress with its lead platform technology Progenza™, partnership with the Australian Department of Defence for Sygenus and ongoing strategy. Please note, the webinar will not cover financial updates.

To register for the webcast, please follow this link:

https://us02web.zoom.us/webinar/register/WN_QdON4FErR3Woy4dxASFnZQ

Investors will have an opportunity to place questions during the live Q&A portion of the webcast or can submit a question ahead of time when registering.

Registered participants will receive a confirmation email containing the Zoom access link and alternative phone dial-in details.

- ENDS -

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. Regeneus' regenerative platform technologies Progenza™ and Sygenus seek to address unmet medical needs in human health markets, focusing on neuropathic pain, osteoarthritis and various skin conditions.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

Hannah Howlett
WE Communications
M: +61 450 648 064
E: WE-AURegeneus@we-worldwide.com